Criteria for Use of Moxifloxacin Ophthalmic Solution

VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel

December 2006

These criteria were based on the best clinical evidence currently available. The recommendations in this document are dynamic, and will be revised as new clinical information becomes available. This guidance is intended to assist practitioners in providing consistent, high-quality, cost-effective drug therapy. These criteria are not intended to interfere with clinical judgment; the clinician must ultimately decide the course of therapy based on individual patient situations. All use of this product outside of the finalized CFU will be reviewed on a case-by-case basis at the direction of the local Pharmacy & Therapeutics Committee.

<table>
<thead>
<tr>
<th>One of the following criteria must be met</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Documented resistant ocular pathogens causing eye infections</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>OR</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Treatment of refractory conjunctivitis, corneal ulcers and keratitis</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>OR</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Patients undergoing eye surgery (i.e., cataract, corneal, retinal or refractive) to minimize risk of endophthalmitis</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>OR</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Atypical ocular infections (i.e. mycobacterium)</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

References

1. Yee RW, Setabutr P, Foltermann MO et al. The effects of topical moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution on corneal healing after bilateral photorefractive keratectomy. Cornea. 2006 Oct;25(9 Suppl 2):S8-S11.


14. Durrie DS, Trattler W. A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. J Ocul Pharmacol Ther. 2005 Jun;21(3):236-41.


